Pharmacie365 Penetrates the French Market With New Quit Smoking Aids

Friday, January 8, 2010 Alcohol & Drug Abuse News J E 4
Jan 7, 2010 Paris, France Pharmacie365, the online drugstore popular for selling Viagra, Cialis, and Levitra at discounted prices, proudly sells discounted quit smoking products at discounted prices as well.

Quit smoking aids, which until recently did not do very well in France, have shown a tremendous turnaround in sales. The increase in sales for products generic Zyban, and E-Cigarettes, follows a successful anti-smoking campaign led by Pharmacie365 in conjunction with local hospitals and cancer research funds.

Yvette Johnson, Campaign Spokeswoman for Pharmacie365, explains, "The French market has been notoriously resistant to quitting smoking, more than most other nations in the world who embrace the goal. They seem skeptical of the health and environmental risks involved with inhaling tobacco products. Until recently, that is. Perhaps its recent health studies, the economic situation, or perhaps just the lapse of time, but French people, as a whole, seem to be finally moving in the right direction on the anti-smoking debate. Were glad that were available to them at this crucial turning point, to help them move away from cigarettes and closer to a smoke-free life, personally and on a global scale as well."

Johnson elaborates on customer support by highlighting Pharmacie365s 24/7 medical helpline. This free service is available to assist clients in choosing medications, discussing side effects, and providing overall support. Pharmacie365s drugs are available online without a prior prescription. Shipping is quick and discreet.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
3SBio Inc. Applies for SFDA Registrational Trial f...
Stryker to Present at Investor Conference